Conflict of interest statement: CONFLICTS OF INTEREST LJ, MF, MK, KD and KKdeclare that they have no potential conflicts of interest with respect to theresearch, authorship, and/or publication of this article.31. Oncotarget. 2018 Apr 3;9(25):17334-17348. doi: 10.18632/oncotarget.24671.eCollection 2018 Apr 3.Full in-frame exon 3 skipping of BRCA2 confers high risk of breast and/or ovariancancer.Caputo SM(1), Léone M(2), Damiola F(3), Ehlen A(4)(5), Carreira A(4)(5), Gaidrat P(6), Martins A(6), Brandão RD(7), Peixoto A(8), Vega A(8), Houdayer C(1)(9),Delnatte C(10), Bronner M(11), Muller D(12), Castera L(13), Guillaud-BatailleM(14), Søkilde I(15), Uhrhammer N(16), Demontety S(1), Tubeuf H(6)(17), CastelainG(6); French COVAR group collaborators, Jensen UB(18), Petitalot A(1), KriegerS(13), Lefol C(1), Moncoutier V(1), Boutry-Kryza N(2), Nielsen HR(19),Sinilnikova O(2), Stoppa-Lyonnet D(1)(9), Spurdle AB(20), Teixeira MR(8)(21),Coulet F(22), Thomassen M(23), Rouleau E(1).Author information: (1)Institut Curie, Service de Génétique, Paris, France.(2)Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, HospicesCivils de Lyon/Centre Léon Bérard, Lyon, France.(3)Centre Léon Bérard, Lyon, France.(4)Institut Curie, PSL Research University, CNRS UMR3348, Orsay, France.(5)Université Paris Sud, Université Paris-Saclay, CNRS UMR3348, Orsay, France.(6)Inserm-U1245, UNIROUEN, Normandie University, Normandy Centre for Genomic and Personalized Medicine, Rouen, France.(7)Maastricht University, Maastricht, Netherlands.(8)Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.(9)Université Paris Descartes, Paris, France.(10)Service de Génétique médicale, CHU Nantes, Nantes, France.(11)Service de Génétique, CHU Nancy Brabois, Nancy, France.(12)Laboratoire d'Oncogénétique, Centre Paul Strauss, Strasbourg, France.(13)Laboratoire de biologie et de génétique du cancer, CLCC François Baclesse,INSERM 1079 Centre Normand de Génomique et de Médecine Personnalisée, Caen,France.(14)Institut Gustave Roussy, Villejuif, France.(15)Section of Molecular Diagnostics, Department of Clinical Biochemistry,Aalborg University Hospital, Aalborg, Denmark.(16)Laboratoire de Biologie Médicale, CLCC Jean Perrin, Clermont-Ferrand, France.(17)Interactive Biosoftware, Rouen, France.(18)Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.(19)Department of Clinical Genetics, Vejle Hospital, Odense, Denmark.(20)Genetics and Comp utational Biology Division, QIMR Berghofer Medical ResearchInstitute, Herston, Brisbane, Australia.(21)Institute of Biomedical Sciences, University of Porto, Porto, Portugal.(22)Laboratoire d'Oncogénétique et d'Angiogénétique Moléculaire, GroupeHospitalier Pitié-Salpêtrière, Paris, France.(23)Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.Germline pathogenic variants in the BRCA2 gene are associated with a cumulativehigh risk of breast/ovarian cancer. Several BRCA2 variants result in completeloss of the exon-3 at the transcript level. The pathogenicity of these variantsand the functional impact of loss of exon 3 have yet to be established. As acollaboration of the COVAR clinical trial group (France), and the ENIGMAconsortium for investigating breast cancer gene variants, this study evaluated 8 BRCA2 variants resulting in complete deletion of exon 3. Clinical information for39 families was gathered from Portugal, France, Denmark and Sweden.Multifactorial likelihood analyses were conducted using information from 293patients, for 7 out of the 8 variants (including 6 intronic). For all variantscombined the likelihood ratio in favor of causality was 4.39*1025. These results provide convincing evidence for the pathogenicity of all examined variants thatlead to a total exon 3 skipping, and suggest that other variants that result incomplete loss of exon 3 at the molecular level could be associated with a highrisk of cancer comparable to that associated with classical pathogenic variantsin BRCA1 or BRCA2 gene. In addition, our functional study shows, for the firsttime, that deletion of exon 3 impairs the ability of cells to survive uponMitomycin-C treatment, supporting lack of function for the altered BRCA2 protein in these cells. Finally, this study demonstrates that any variant leading toexpression of only BRCA2 delta-exon 3 will be associated with an increased riskof breast and ovarian cancer.DOI: 10.18632/oncotarget.24671 PMCID: PMC5915120PMID: 29707112 